MX9701384A - Vacuna viva para el tratamiento de enfermedades tumorales. - Google Patents
Vacuna viva para el tratamiento de enfermedades tumorales.Info
- Publication number
- MX9701384A MX9701384A MX9701384A MX9701384A MX9701384A MX 9701384 A MX9701384 A MX 9701384A MX 9701384 A MX9701384 A MX 9701384A MX 9701384 A MX9701384 A MX 9701384A MX 9701384 A MX9701384 A MX 9701384A
- Authority
- MX
- Mexico
- Prior art keywords
- vaccine
- cells
- tumour
- cell
- live
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 9
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 229940030156 cell vaccine Drugs 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 3
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 108020004440 Thymidine kinase Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000010353 genetic engineering Methods 0.000 abstract 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invencion se relaciona con la preparacion y uso de una vacuna de células tumorales vivas, la cual contiene tres genes adicionales preparados por técnicas de ingeniería genética: a) el gen que codifica para una proteína de la superficie celular con actividad inmunoestimuladora, b) un gen de citosina y c) el gen de timidina cinasa. Los campos de aplicacion de la invencion son la medicina y la ingeniería genética. La vacuna viva propuesta debe su efecto al hecho de que es inducida una respuesta antitumoral sinérgica por la transferencia multiple de genes que codifican par ala actividad inmunoestimuladora. Esto conduce a la repulsion confiable de las células de la vacuna que sean inyectadas por células capaces de multiplicarse como una vacuna. Como un marcador seguro adicional, las células de la vacuna son dotadas con los genes de la timidina cinasa, lo cual permite que las células de la vacuna sean eliminadas selectivamente in vivo. La expresion combinada de los genes con actividad inmunoestimuladora mejora el efecto de la vacuna en comparacion con las vacunas de células tumorales de la técnica anterior, y una vacuna de células tumorales vivas es más efectiva que una vacuna que consiste de células que son incapaces de multiplicarse. Se pretende que la vacuna sea usada en la terapia genética de los pacientes con cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4431401.9 | 1994-08-24 | ||
| DE4431401A DE4431401A1 (de) | 1994-08-24 | 1994-08-24 | Lebendvakzine gegen Tumorerkrankungen |
| PCT/DE1995/001164 WO1996005866A2 (de) | 1994-08-24 | 1995-08-18 | Lebendvakzine zur behandlung von tumorerkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9701384A true MX9701384A (es) | 1998-03-31 |
| MXPA97001384A MXPA97001384A (es) | 1998-10-15 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| BR9508765A (pt) | 1997-11-11 |
| AU3253195A (en) | 1996-03-14 |
| DE4431401A1 (de) | 1996-02-29 |
| KR970705416A (ko) | 1997-10-09 |
| ATE228016T1 (de) | 2002-12-15 |
| DK0777499T3 (da) | 2003-03-17 |
| JP2975117B2 (ja) | 1999-11-10 |
| US6039941A (en) | 2000-03-21 |
| WO1996005866A3 (de) | 1996-04-11 |
| EP0777499A1 (de) | 1997-06-11 |
| EP0777499B1 (de) | 2002-11-20 |
| AU688101B2 (en) | 1998-03-05 |
| DE19580890D2 (de) | 1997-06-19 |
| WO1996005866A2 (de) | 1996-02-29 |
| JPH10505339A (ja) | 1998-05-26 |
| PT777499E (pt) | 2003-03-31 |
| ES2187568T3 (es) | 2003-06-16 |
| DE59510466D1 (de) | 2003-01-02 |
| CA2198234A1 (en) | 1996-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996005866A3 (de) | Lebendvakzine zur behandlung von tumorerkrankungen | |
| DE60107203D1 (de) | Herpes-virusstämme für die gentherapie | |
| ES2167365T3 (es) | Vectores adenovirales de origen animal y utilizacion en terapia genica. | |
| IL144371A0 (en) | Her-2/neu fusion proteins | |
| AP2003002937A0 (en) | One dose vaccination with mycoplasma hyopneumoniae | |
| EP1315512A4 (en) | TARGETED INTRODUCTION USING ADENOVIRES AND ADENOVIRAL MANIPULATION IMMUNES SYSTEM RESPONSE USING TARGETED PEPTIDES | |
| DK0784483T3 (da) | Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul | |
| MX9700229A (es) | Vacuna de polinucleotido para virus de papiloma. | |
| GR3020557T3 (en) | Oligonucleotide alkylphosphonates and alkylphosphonothioates. | |
| ATE192500T1 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
| PH12020500239A1 (en) | Factor viii (fviii) gene therapy methods | |
| GB9402857D0 (en) | Targeting gene therapy | |
| PT1200590E (pt) | Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo | |
| WO2022195074A3 (en) | Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy | |
| CN103110939A (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| DE69434244D1 (de) | Verbesserte krebstherapie | |
| BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
| ATE307886T1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
| BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
| IL121272A0 (en) | Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug | |
| MXPA02005506A (es) | Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo. | |
| ZA202304877B (en) | Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof | |
| Clark et al. | Biologic treatment of human cancer | |
| EP1642981A4 (en) | MEDICINE BY RECOMBINANT GENE OF ADENOVIRUS VECTOR AND P53 GENE FOR TREATING PROLIFERATIVE DISEASES | |
| DE69730967D1 (en) | Human dnase ii |